School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
State Key Laboratory of Oncogene and Related Genes & Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cancer Epidemiol Biomarkers Prev. 2022 Nov 2;31(11):2046-2053. doi: 10.1158/1055-9965.EPI-22-0439.
Many studies suggested that menstrual and reproductive factors affected the gender disparity in liver carcinogenesis, but the results were inconsistent. Moreover, there are few studies in Asian populations. Therefore, our study was to explore the association of menstrual and reproductive factors on liver cancer risk in Chinese women.
72,807 women were recruited in 1996 to 2000 and followed until the end of 2016 in Shanghai, China. Cox regression models were used to estimate HRs and 95% confidence intervals (CIs) for the association of menstrual and reproductive factors with liver cancer.
258 liver cancer cases were identified during 1,269,531 person-years of follow-up. In premenopausal and postmenopausal women, hormone replacement therapy (HRT) and injective contraceptives were positively associated with liver cancer risk respectively (HR, 1.23, 95% CI, 1.15-1.30; HR, 1.23, 95% CI, 1.17-1.30; HR, 1.07, 95% CI, 1.05-1.10; HR, 1.08, 95% CI, 1.05-1.11), while older age at menopause, longer reproductive period and fewer live births were associated with reduced risk, especially among postmenopausal women (Ptrend < 0.05). In addition, liver cancer risk was elevated in postmenopausal women who received hysterectomy (HR, 1.07; 95% CI, 1.04-1.11), oophorectomy (HR, 1.05; 95% CI, 1.01-1.10) or oral contraceptives (HR, 1.06; 95% CI, 1.03-1.08). No association was found between age at menarche and liver cancer risk. Similar results were observed when excluding participants with less than 2 follow-up years.
The findings suggested that female sex hormones could play significant roles in liver carcinogenesis.
Our study was the first population-based cohort to provide epidemiology evidence of menstrual and reproductive factors on liver cancer risk in Chinese women.
许多研究表明,月经和生殖因素会影响肝癌的性别差异,但结果并不一致。此外,亚洲人群的研究较少。因此,我们的研究旨在探讨中国女性月经和生殖因素与肝癌风险的关系。
1996 年至 2000 年,在中国上海招募了 72807 名女性,并随访至 2016 年底。Cox 回归模型用于估计月经和生殖因素与肝癌关联的风险比(HR)和 95%置信区间(CI)。
在 1269531 人年的随访中,共发现 258 例肝癌病例。在绝经前和绝经后妇女中,激素替代疗法(HRT)和注射避孕药分别与肝癌风险呈正相关(HR,1.23,95%CI,1.15-1.30;HR,1.23,95%CI,1.17-1.30;HR,1.07,95%CI,1.05-1.10;HR,1.08,95%CI,1.05-1.11),而绝经年龄较大、生育期较长和生育次数较少与风险降低相关,尤其是绝经后妇女(Ptrend < 0.05)。此外,接受子宫切除术(HR,1.07;95%CI,1.04-1.11)、卵巢切除术(HR,1.05;95%CI,1.01-1.10)或口服避孕药(HR,1.06;95%CI,1.03-1.08)的绝经后妇女肝癌风险升高。初潮年龄与肝癌风险之间无关联。当排除随访时间少于 2 年的参与者时,也观察到了类似的结果。
研究结果表明,女性性激素可能在肝癌发生中起重要作用。
我们的研究是第一项基于人群的队列研究,为中国女性月经和生殖因素与肝癌风险之间的关系提供了流行病学证据。